Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As previously reported, on July 03, 2023, Bravo Multinational, Inc. (“BRAVO”), a corporation formed under the laws of the State of Wyoming, entered into a Share Exchange Agreement (“the Agreement”) with Recombinant Productions Inc. (“RPI”), a corporation formed under the laws of the State of Nevada. Under the terms of the Agreement, the RPI shareholders will exchange shares representing approximately 51% of the outstanding shares of RPI common stock to BRAVO in exchange for 8,500,000 shares of BRAVO common stock.

On July 13, 2023, this transaction closed in accordance with terms of the Stock Purchase Agreement previously filed.

This Amendment No. 1 to our Current Report on Form 8-K is being filed to report the financial information that was required to be presented as a result of the closing described in our earlier Current Reports referenced herein.

Recombinant Productions, Inc. (“RPI”) is a Nevada corporation that is engaged in the business of developing and acquiring entertainment content and related technologies that span both traditional and new media distribution platforms.

Certain statements contained in this current report on Form 8-K are forward-looking statements and are based on future expectations, plans and prospects for BRAVO’s business and operations and involve a number of risks and uncertainties. BRAVO’s forward-looking statements in this report are made as of the date hereof and BRAVO disclaims any duties to supplement, update or revise such statements on a going forward basis whether as a result of subsequent developments, change or expectations or otherwise. In connection with the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995, BRAVO is identifying certain forward-looking information regarding, among other things, the Important factors that could cause further events or results to vary from those addressed in the forward-looking statements, including, without limitation, risks and uncertainties arising from the ability of BRAVO to successfully manage the acquisition of RPI; uncertainties relating to the ability to realize the expected benefits of the share exchange; unanticipated or unfavourable regulatory matters; general economic conditions in the region and industry in which the companies operate, and other risk factors as discussed in other BRAVO filings made from time to time with the United States Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

We have audited the accompanying balance sheet of Recombinant Productions Inc. (the “Company”) as of June 30, 2023, the related statement of operations, stockholders’ equity (deficit), and cash flows for the period June 15, 2023 (Inception) through June 30, 2023 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2023, and the results of its operations and its cash flows for the period June 15, 2023 (Inception) through June 30, 2023, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 4 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 4. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

The accompanying notes are an integral part of these unaudited financial statements.


Wyoming	000-53505	85-4068651
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

(Address of principal executive offices) 2020 General Booth Blvd., Suite 230 Virginia Beach, VA 23454


Report of Independent Registered Public Accounting Firm	4
Condensed Balance Sheet at June 30, 2023 – Aaudited	5
Condensed Statement of Operations for the Three Months Ended June 30, 2023 – Audited	6
Condensed Statement of Cash Flows for the Three Months Ended June 30, 2023 – Audited	7
Condensed Statement of Stockholders’ Deficit for the Three Months Ended June 30, 2023–Audited	8
Notes to the Condensed Unaudited Financial Statements	9-10


	(Audited)
	June 30,
	2023

ASSETS
Current Assets
Cash	$	-

Total Assets	$	-

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities
Accounts Payable	$	1,000

Total Current Liabilities		1,000

Total Liabilities		1,000

Stockholders’ Deficit
Common Stock - $0.001 Par; 10,000 Shares Authorized, 10,000 Issued and Outstanding		10
Additional Paid-In-Capital		844
Accumulated Deficit		(1,854	)

Total Stockholders’ Deficit		(1,000	)

Total Liabilities and Stockholders’ Deficit	$	-


From June 15, 2023 (Date of Inception) to June 30,	2023

Revenue	$	-

Operating Expenses
General and Administrative - Organization Expense		1,854

Total Operating Expenses		1,854

Net Loss for the Period	$	(1,854	)

Weighted Average Number of Common Shares - Basic and Diluted		9,667

Net Loss for the Period Per Common Shares - Basic and Diluted	$	(0.19	)


From June 15, 2023 (Date of Inception) to June 30,	2023

Cash Flows from Operating Activities

Net Loss for the Period	$	(1,854	)

Changes in Assets and Liabilities:
Accounts Payable and Accrued Liabilities		1,000

Net Cash Flows Used In Operating Activities		(854	)

Cash Flows from Investing Activities		-

Cash Flows from Financing Activities
Capital Contributions		854

Net Cash Flows Provided By Financing Activities		854

Net Change in Cash		-

Cash - Beginning of Period		-

Cash - End of Period	$	-

Cash Paid During the Period for:
Interest	$	-
Income Taxes	$	-

Schedule of Non-Cash Transactions:
Issuance of Common Stock	$	10


	Common Stock				Additional						Total
	$0.001 Par				Paid-In			Accumulated			Stockholders’
	Shares		Amount		Capital			Deficit			Deficit
Balance - June 15, 2023 Inception		-	$	-	$	-		$	-		$	-

Issuance of Common Stock		10,000		10		(10	)		-			-

Capital Contributions		-		-		854			-			854

Net Loss for the Period		-		-		-			(1,854	)		(1,854	)

Balance - June 30, 2023		10,000	$	10	$	844		$	(1,854	)	$	(1,000	)

Schedule of finanical information
	Bravo Multinational			Recombinant Productions Inc.			Proforma Adjustments			Proforma
ASSETS
Current Assets
Cash	$	2,535		$	-					$	2,535
Prepaids		29,325			-						29,325

Total Assets	$	31,860		$	-					$	31,860

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued expenses	$	8,936		$	1,000					$	9,936
Customer deposits		35,800			-						35,800
Due to related parties		66,230			-						66,230
Accrued board of directors fees		119,750			-						119,750
Total Liabilities		230,716			1,000						231,716

Stockholders’ Deficit:
Common Stock		4,763			10			(10	)(1)		5,613
								850	(2)
Additional paid-in capital		90,954,399			844			10	(1)		95,034,403
								4,079,150	(2)
Accumulated deficit		(90,940,720	)		-			-			(90,940,720	)

Net loss		(217,298	)		(1,854	)		(4,080,000	)		(4,299,152	)
Accumulated deficit		(91,158,018	)		(1,854	)		-			(91,159,872	)
Total Stockholders’ Deficit		(198,856	)		(1,000	)		-			(199,856	)

Total Liabilities and Stockholders’ Deficit	$	31,860		$	-		$	-		$	31,860